Advertisement
| cell therapy market size: Cell and Gene Therapies Miguel-Angel Perales, Syed A. Abutalib, Catherine Bollard, 2018-11-27 In this book, experts in the field express their well-reasoned opinions on a range of complex, clinically relevant issues across the full spectrum of cell and gene therapies with the aim of providing trainee and practicing hematologists, including hematopoietic transplant physicians, with information that is relevant to clinical practice and ongoing research. Each chapter focuses on a particular topic, and the concise text is supported by numerous working tables, algorithms, and figures. Whenever appropriate, guidance is provided regarding the availability of potentially high-impact clinical trials. The rapid evolution of cell and gene therapies is giving rise to numerous controversies that need to be carefully addressed. In meeting this challenge, this book will appeal to all residents, fellows, and faculty members responsible for the care of hematopoietic cell transplant patients. It will also offer a robust, engaging tool to aid vital activities in the daily work of every hematology and oncology trainee. |
| cell therapy market size: Stem Cell Manufacturing Joaquim M.S. Cabral, Claudia Lobato da Silva, Lucas G. Chase, M. Margardia Diogo, 2016-07-24 Stem Cell Manufacturing discusses the required technologies that enable the transfer of the current laboratory-based practice of stem cell tissue culture to the clinic environment as therapeutics, while concurrently achieving control, reproducibility, automation, validation, and safety of the process and the product. The advent of stem cell research unveiled the therapeutic potential of stem cells and their derivatives and increased the awareness of the public and scientific community for the topic. The successful manufacturing of stem cells and their derivatives is expected to have a positive impact in the society since it will contribute to widen the offer of therapeutic solutions to the patients. Fully defined cellular products can be used to restore the structure and function of damaged tissues and organs and to develop stem cell-based cellular therapies for the treatment of cancer and hematological disorders, autoimmune and other inflammatory diseases and genetic disorders. - Presents the first 'Flowchart' of stem cell manufacturing enabling easy understanding of the various processes in a sequential and coherent manner - Covers all bioprocess technologies required for the transfer of the bench findings to the clinic including the process components: cell signals, bioreactors, modeling, automation, safety, etc. - Presents comprehensive coverage of a true multidisciplinary topic by bringing together specialists in their particular area - Provides the basics of the processes and identifies the issues to be resolved for large scale cell culture by the bioengineer - Addresses the critical need in bioprocessing for the successful delivery of stem cell technology to the market place by involving professional engineers in sections of the book |
| cell therapy market size: Gene and Cell Therapies Eve Hanna, Mondher Toumi, 2020-05-19 The major advances in the field of biotechnology and molecular biology in the twenty-first century have led to a better understanding of the pathophysiology of diseases. A new generation of biopharmaceuticals has emerged, including a wide and heterogeneous range of innovative cell and gene therapies. These therapies aim to prevent or treat chronic and serious life-threatening diseases, previously considered incurable. This book describes the evolution and adaptation of the regulatory environment to assess these therapies in contrast with the resistance of health technology assessment (HTA) agencies and payers to acknowledge the specificity of cell and gene therapies and the need to adapt existing decision-making frameworks. This book provides insights on the learnings from the experience of current cell and gene therapies (regulatory approval, HTA, and market access), in addition to future trends to enhance patient access to these therapies. Key Features: Describes the potential change of treatment paradigm and the specificity of cell and gene therapies, including the gradual move from repeated treatment administration to one-time single administration with the potential to be definite cure Highlights the challenges at the HTA level Discusses the affordability of future cell and gene therapies and the possible challenges for health insurance systems Provides potential solutions to address these challenges and ensure patient access to innovation while maintaining the sustainability of healthcare systems |
| cell therapy market size: Advances In Pharmaceutical Cell Therapy: Principles Of Cell-based Biopharmaceuticals Christine Guenther, Andrea Josefine Hauser, Ralf Huss, 2015-09-23 This textbook is a comprehensive overview of the development of cell-based biopharmaceuticals. Beginning with the underlying biology of stem cell and cell-based products, it traces the long and complex journey from preclinical concept to initiation of a pivotal clinical trial and the potential business model behind it.The book also takes into consideration the different regulatory landscapes and their continuous evolution in Europe, North America and other parts of the world. The authors describe a path to manufacture a clinical grade therapeutic that passes all necessary quality measures as a robust and marketable product including an outlook on next generation products and innovative strategies.This reference book is a must-have guide for any professional already active in biopharmaceuticals and anyone interested in getting involved in a scientific, medical or business capacity. |
| cell therapy market size: Regulatory Aspects of Gene Therapy and Cell Therapy Products Maria Cristina Galli, Mercedes Serabian, 2015-09-15 This book discusses the different regulatory pathways for gene therapy (GT) and cell therapy (CT) medicinal products implemented by national and international bodies throughout the world (e.g. North and South America, Europe, and Asia). Each chapter, authored by experts from various regulatory bodies throughout the international community, walks the reader through the applications of nonclinical research to translational clinical research to licensure for these innovative products. More specifically, each chapter offers insights into fundamental considerations that are essential for developers of CT and GT products, in the areas of product manufacturing, pharmacology and toxicology, and clinical trial design, as well as pertinent must-know guidelines and regulations. Regulatory Aspects of Gene Therapy and Cell Therapy Products: A Global Perspective is part of the American Society of Gene and Cell Therapy sub-series of the highly successful Advances in Experimental Medicine and Biology series. It is essential reading for graduate students, clinicians, and researchers interested in gene and cell therapy and the regulation of pharmaceuticals. |
| cell therapy market size: Exploring Novel Clinical Trial Designs for Gene-Based Therapies National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Forum on Regenerative Medicine, 2020-08-27 Recognizing the potential design complexities and ethical issues associated with clinical trials for gene therapies, the Forum on Regenerative Medicine of the National Academies of Sciences, Engineering, and Medicine held a 1-day workshop in Washington, DC, on November 13, 2019. Speakers at the workshop discussed patient recruitment and selection for gene-based clinical trials, explored how the safety of new therapies is assessed, reviewed the challenges involving dose escalation, and spoke about ethical issues such as informed consent and the role of clinicians in recommending trials as options to their patients. The workshop also included discussions of topics related to gene therapies in the context of other available and potentially curative treatments, such as bone marrow transplantation for hemoglobinopathies. This publication summarizes the presentation and discussion of the workshop. |
| cell therapy market size: Biopharmaceutical Processing Gunter Jagschies, Eva Lindskog, Karol Lacki, Parrish M. Galliher, 2018-01-18 Biopharmaceutical Processing: Development, Design, and Implementation of Manufacturing Processes covers bioprocessing from cell line development to bulk drug substances. The methods and strategies described are essential learning for every scientist, engineer or manager in the biopharmaceutical and vaccines industry. The integrity of the bioprocess ultimately determines the quality of the product in the biotherapeutics arena, and this book covers every stage including all technologies related to downstream purification and upstream processing fields. Economic considerations are included throughout, with recommendations for lowering costs and improving efficiencies. Designed for quick reference and easy accessibility of facts, calculations and guidelines, this book is an essential tool for industrial scientists and managers in the biopharmaceutical industry. - Offers a comprehensive, go-to reference for daily work decisions - Covers both upstream and downstream processes - Includes case studies that emphasize financial outcomes - Presents summaries, decision grids, graphs and overviews for quick reference |
| cell therapy market size: Stem Cells and the Future of Regenerative Medicine Institute of Medicine, Board on Neuroscience and Behavioral Health, National Research Council, Division on Earth and Life Studies, Board on Life Sciences, Committee on the Biological and Biomedical Applications of Stem Cell Research, 2002-01-25 Recent scientific breakthroughs, celebrity patient advocates, and conflicting religious beliefs have come together to bring the state of stem cell researchâ€specifically embryonic stem cell researchâ€into the political crosshairs. President Bush's watershed policy statement allows federal funding for embryonic stem cell research but only on a limited number of stem cell lines. Millions of Americans could be affected by the continuing political debate among policymakers and the public. Stem Cells and the Future of Regenerative Medicine provides a deeper exploration of the biological, ethical, and funding questions prompted by the therapeutic potential of undifferentiated human cells. In terms accessible to lay readers, the book summarizes what we know about adult and embryonic stem cells and discusses how to go about the transition from mouse studies to research that has therapeutic implications for people. Perhaps most important, Stem Cells and the Future of Regenerative Medicine also provides an overview of the moral and ethical problems that arise from the use of embryonic stem cells. This timely book compares the impact of public and private research funding and discusses approaches to appropriate research oversight. Based on the insights of leading scientists, ethicists, and other authorities, the book offers authoritative recommendations regarding the use of existing stem cell lines versus new lines in research, the important role of the federal government in this field of research, and other fundamental issues. |
| cell therapy market size: Translational Regenerative Medicine Anthony Atala, Julie Allickson, 2014-12-01 Translational Regenerative Medicine is a reference book that outlines the life cycle for effective implementation of discoveries in the dynamic field of regenerative medicine. By addressing science, technology, development, regulatory, manufacturing, intellectual property, investment, financial, and clinical aspects of the field, this work takes a holistic look at the translation of science and disseminates knowledge for practical use of regenerative medicine tools, therapeutics, and diagnostics. Incorporating contributions from leaders in the fields of translational science across academia, industry, and government, this book establishes a more fluid transition for rapid translation of research to enhance human health and well-being. - Provides formulaic coverage of the landscape, process development, manufacturing, challenges, evaluation, and regulatory aspects of the most promising regenerative medicine clinical applications - Covers clinical aspects of regenerative medicine related to skin, cartilage, tendons, ligaments, joints, bone, fat, muscle, vascular system, hematopoietic /immune system, peripheral nerve, central nervous system, endocrine system, ophthalmic system, auditory system, oral system, respiratory system, cardiac system, renal system, hepatic system, gastrointestinal system, genitourinary system - Identifies effective, proven tools and metrics to identify and pursue clinical and commercial regenerative medicine |
| cell therapy market size: Mesenchymal Stem Cell Therapy Lucas G. Chase, Mohan C Vemuri, 2012-12-12 Over the past decade, significant efforts have been made to develop stem cell-based therapies for difficult to treat diseases. Multipotent mesenchymal stromal cells, also referred to as mesenchymal stem cells (MSCs), appear to hold great promise in regards to a regenerative cell-based therapy for the treatment of these diseases. Currently, more than 200 clinical trials are underway worldwide exploring the use of MSCs for the treatment of a wide range of disorders including bone, cartilage and tendon damage, myocardial infarction, graft-versus-host disease, Crohn’s disease, diabetes, multiple sclerosis, critical limb ischemia and many others. MSCs were first identified by Friendenstein and colleagues as an adherent stromal cell population within the bone marrow with the ability to form clonogenic colonies in vitro. In regards to the basic biology associated with MSCs, there has been tremendous progress towards understanding this cell population’s phenotype and function from a range of tissue sources. Despite enormous progress and an overall increased understanding of MSCs at the molecular and cellular level, several critical questions remain to be answered in regards to the use of these cells in therapeutic applications. Clinically, both autologous and allogenic approaches for the transplantation of MSCs are being explored. Several of the processing steps needed for the clinical application of MSCs, including isolation from various tissues, scalable in vitro expansion, cell banking, dose preparation, quality control parameters, delivery methods and numerous others are being extensively studied. Despite a significant number of ongoing clinical trials, none of the current therapeutic approaches have, at this point, become a standard of care treatment. Although exceptionally promising, the clinical translation of MSC-based therapies is still a work in progress. The extensive number of ongoing clinical trials is expected to provide a clearer path forward for the realization and implementation of MSCs in regenerative medicine. Towards this end, reviews of current clinical trial results and discussions of relevant topics association with the clinical application of MSCs are compiled in this book from some of the leading researchers in this exciting and rapidly advancing field. Although not absolutely all-inclusive, we hope the chapters within this book can promote and enable a better understanding of the translation of MSCs from bench-to-bedside and inspire researchers to further explore this promising and quickly evolving field. |
| cell therapy market size: Assessing and Improving Value in Cancer Care Institute of Medicine, Board on Health Care Services, National Cancer Policy Forum, 2009-11-30 Unlike many other areas in health care, the practice of oncology presents unique challenges that make assessing and improving value especially complex. First, patients and professionals feel a well-justified sense of urgency to treat for cure, and if cure is not possible, to extend life and reduce the burden of disease. Second, treatments are often both life sparing and highly toxic. Third, distinctive payment structures for cancer medicines are intertwined with practice. Fourth, providers often face tremendous pressure to apply the newest technologies to patients who fail to respond to established treatments, even when the evidence supporting those technologies is incomplete or uncertain, and providers may be reluctant to stop toxic treatments and move to palliation, even at the end of life. Finally, the newest and most novel treatments in oncology are among the most costly in medicine. This volume summarizes the results of a workshop that addressed these issues from multiple perspectives, including those of patients and patient advocates, providers, insurers, health care researchers, federal agencies, and industry. Its broad goal was to describe value in oncology in a complete and nuanced way, to better inform decisions regarding developing, evaluating, prescribing, and paying for cancer therapeutics. |
| cell therapy market size: Stem Cell Therapy: A Rising Tide: How Stem Cells Are Disrupting Medicine and Transforming Lives Neil H. Riordan, 2017-06-20 Stem cells are the repair cells of your body. When there aren't enough of them, or they aren't working properly, chronic diseases can manifest and persist. From industry leaders, sport stars, and Hollywood icons to thousands of everyday, ordinary people, stem cell therapy has helped when standard medicine failed. Many of them had lost hope. These are their stories. Neil H Riordan, author of MSC: Clinical Evidence Leading Medicine's Next Frontier, the definitive textbook on clinical stem cell therapy, brings you an easy-to-read book about how and why stem cells work, and why they're the wave of the future. |
| cell therapy market size: The Business of Healthcare Innovation Lawton Robert Burns, 2005-08-25 The Business of Healthcare Innovation is the first wide-ranging analysis of business trends in the manufacturing segment of the health care industry. In this leading edge volume, Professor Burns focuses on the key role of the 'producers' as the main source of innovation in health systems. Written by professors of the Wharton School and industry executives, this book provides a detailed overview of the pharmaceutical, biotechnology, genomics/proteomics, medical device and information technology sectors. It analyses the market structures of these sectors as well as the business models and corporate strategies of firms operating within them. Most importantly, the book describes the growing convergence between these sectors and the need for executives in one sector to increasingly draw upon trends in the others. It will be essential reading for students and researchers in the field of health management, and of great interest to strategy scholars, industry practitioners and management consultants. |
| cell therapy market size: Cell Therapy Adrian Gee, 2009-09-18 Cell Therapy: cGMP Facilities and Manufacturing is the source for a complete discussion of facility design and operation with practical approaches to a variety of day-to-day activities, such as staff training and competency, cleaning procedures, and environmental monitoring. This in-depth book also includes detailed reviews of quality, the framework of regulations, and professional standards. It meets a previously unmet need for a thorough facility-focused resource, Cell Therapy: cGMP Facilities and Manufacturing will be an important addition to the cell therapy professional’s library. Additional topics in Cell Therapy: cGMP Facilities and Manufacturing...Standard operating procedures - Supply management - Facility equipment - Product manufacturing, review, release and administration - Facility master file. |
| cell therapy market size: Ask a Manager Alison Green, 2018-05-01 From the creator of the popular website Ask a Manager and New York’s work-advice columnist comes a witty, practical guide to 200 difficult professional conversations—featuring all-new advice! There’s a reason Alison Green has been called “the Dear Abby of the work world.” Ten years as a workplace-advice columnist have taught her that people avoid awkward conversations in the office because they simply don’t know what to say. Thankfully, Green does—and in this incredibly helpful book, she tackles the tough discussions you may need to have during your career. You’ll learn what to say when • coworkers push their work on you—then take credit for it • you accidentally trash-talk someone in an email then hit “reply all” • you’re being micromanaged—or not being managed at all • you catch a colleague in a lie • your boss seems unhappy with your work • your cubemate’s loud speakerphone is making you homicidal • you got drunk at the holiday party Praise for Ask a Manager “A must-read for anyone who works . . . [Alison Green’s] advice boils down to the idea that you should be professional (even when others are not) and that communicating in a straightforward manner with candor and kindness will get you far, no matter where you work.”—Booklist (starred review) “The author’s friendly, warm, no-nonsense writing is a pleasure to read, and her advice can be widely applied to relationships in all areas of readers’ lives. Ideal for anyone new to the job market or new to management, or anyone hoping to improve their work experience.”—Library Journal (starred review) “I am a huge fan of Alison Green’s Ask a Manager column. This book is even better. It teaches us how to deal with many of the most vexing big and little problems in our workplaces—and to do so with grace, confidence, and a sense of humor.”—Robert Sutton, Stanford professor and author of The No Asshole Rule and The Asshole Survival Guide “Ask a Manager is the ultimate playbook for navigating the traditional workforce in a diplomatic but firm way.”—Erin Lowry, author of Broke Millennial: Stop Scraping By and Get Your Financial Life Together |
| cell therapy market size: Continuous Renal Replacement Therapy John A. Kellum, Rinaldo Bellomo, Claudio Ronco, 2016 Continuous Renal Replacement Therapy provides concise, evidence-based, bedside guidance for the management of critically ill patients with acute renal failure, offering quick reference answers to clinicians' questions about treatments and situations encountered in daily practice. |
| cell therapy market size: Clinical Translation and Commercialisation of Advanced Therapy Medicinal Products Tracy Tong Li Yu, Yves Bayon, Alain A. Vertes, Ivan Martin, 2021-01-21 Dr. Yves Bayon is a Senior Principal Scientist at Medtronic and Dr. Alain Vertes is affiliated with NxR Biotechnologies GmbH. All other Topic Editors declare no competing interests with regards to the Research Topic subject. |
| cell therapy market size: Cellular Therapy Ellen M. Areman, Kathy Loper, 2009 |
| cell therapy market size: Monoclonal Antibody Production National Research Council, Institute for Laboratory Animal Research, Committee on Methods of Producing Monoclonal Antibodies, 1999-05-06 The American Anti-Vivisection Society (AAVS) petitioned the National Institutes of Health (NIH) on April 23, 1997, to prohibit the use of animals in the production of mAb. On September 18, 1997, NIH declined to prohibit the use of mice in mAb production, stating that the ascites method of mAb production is scientifically appropriate for some research projects and cannot be replaced. On March 26, 1998, AAVS submitted a second petition, stating that NIH failed to provide valid scientific reasons for not supporting a proposed ban. The office of the NIH director asked the National Research Council to conduct a study of methods of producing mAb. In response to that request, the Research Council appointed the Committee on Methods of Producing Monoclonal Antibodies, to act on behalf of the Institute for Laboratory Animal Research of the Commission on Life Sciences, to conduct the study. The 11 expert members of the committee had extensive experience in biomedical research, laboratory animal medicine, animal welfare, pain research, and patient advocacy (Appendix B). The committee was asked to determine whether there was a scientific necessity for the mouse ascites method; if so, whether the method caused pain or distress; and, if so, what could be done to minimize the pain or distress. The committee was also asked to comment on available in vitro methods; to suggest what acceptable scientific rationale, if any, there was for using the mouse ascites method; and to identify regulatory requirements for the continued use of the mouse ascites method. The committee held an open data-gathering meeting during which its members summarized data bearing on those questions. A 1-day workshop (Appendix A) was attended by 34 participants, 14 of whom made formal presentations. A second meeting was held to finalize the report. The present report was written on the basis of information in the literature and information presented at the meeting and the workshop. |
| cell therapy market size: Perinatal Stem Cells Anthony Atala, Kyle J. Cetrulo, Rouzbeh R. Taghizadeh, Curtis L Cetrulo, Sean Murphy, 2018-06-14 Perinatal Stem Cells provides researchers and clinicians with a comprehensive description of the current clinical and pre-clinical applications of stem cells derived from perinatal sources, such as amniotic fluid, placenta and placental membranes, the umbilical cord and Wharton's jelly. It's compiled by leading experts in the field, offering readers detailed insights into sources of perinatal stem cells and their potential for disease treatment. Therapeutic applications of perinatal stem cells include the treatment of in utero and pregnancy related diseases, cardiac disease, liver disease, pulmonary disease, inflammatory diseases, for hematopoietic regeneration, and for neural protection after stroke or traumatic brain injury. In addition, the rapid advance in clinical translation and commercialization of perinatal stem cell therapies is highlighted in a section on Clinical and Industry Perspective which provides insight into the new opportunities and challenges involved in this novel and exciting industry. - Explores current clinical and pre-clinical application of stem cells derived from perinatal sources - Offers detailed insight into sources of perinatal stem cells and their potential for disease treatment - Discusses progress in the manufacturing, banking and clinical translation of perinatal stem cells - Edited by a world-renowned team to present a complete story of the development and promise of perinatal stem cells |
| cell therapy market size: Advances in Application of Stem Cells: From Bench to Clinics Firdos Alam Khan, 2021-09-14 The field of stem cell biology is expanding with a continued surge of new information related to its applications. Over past few years, stem cells have been extensively used in cell therapy, tissue engineering, in vitro drug testing among others. At the moment there is no single book available which comprehensively describes the significance of various application of stem cells derived from embryonic and adult sources from lab to clinics. In this edited volume, we discuss basics and advanced topics of stem cells to help researchers, students and professional find the most important information in a single source of updated information about stem cells and relevant applications. This book is divided in 12 chapters and covers topics such as in vitro cell culture, 3D cell culture, cell therapy, tissue engineering, cell factory, cell functionality, in vitro drug testing, organ development, autologous transplantation, allogeneic transplantation, adult stem cells, multipotent stem cells, induced pluripotent stem cells, a pluripotent and embryonic stem cells. |
| cell therapy market size: Rare Diseases and Orphan Products Institute of Medicine, Board on Health Sciences Policy, Committee on Accelerating Rare Diseases Research and Orphan Product Development, 2011-04-03 Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development. |
| cell therapy market size: The Role of NIH in Drug Development Innovation and Its Impact on Patient Access National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Board on Health Care Services, 2020-01-27 To explore the role of the National Institutes of Health (NIH) in innovative drug development and its impact on patient access, the Board on Health Care Services and the Board on Health Sciences Policy of the National Academies jointly hosted a public workshop on July 24â€25, 2019, in Washington, DC. Workshop speakers and participants discussed the ways in which federal investments in biomedical research are translated into innovative therapies and considered approaches to ensure that the public has affordable access to the resulting new drugs. This publication summarizes the presentations and discussions from the workshop. |
| cell therapy market size: Human Pluripotent Stem Cells Philip H. Schwartz, Robin L. Wesselschmidt, 2011-08-09 Almost daily, new technologies are being presented that move the field of human pluripotent stem cell research towards a future that may yield highly-effective, personalized medical treatments. Three enabling technologies at hand for human PSCs are 1) directed reprogramming of somatic cells, which eliminate many of the ethical issues associated with the derivation and use of human PSCs, increase genetic diversity of the available human PSC lines, and give rise to better in vitro human disease models; 2) the discovery that a Rho-associated protein Kinase (ROCK) inhibitor allows for efficient single cell passaging and cryopreservation, increasing the efficiency and reliability of hPSC culture; and 3) defined, animal-component-free media, which lay the groundwork for simplified scale-up for therapeutic applications, differentiation protocols, and toxicology screens. The aforementioned technologies can be found in Human Pluripotent Stem Cells: Methods and Protocols, a compilation of 33 detailed protocols in six categories of PSC research that cover laboratory essentials and the derivation of new PSC lines, including induced PSC lines, as well as their growth, maintenance, characterization, genetic manipulation, and differentiation. Written in the successful Methods in Molecular BiologyTM series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible protocols, and notes on troubleshooting and avoiding known pitfalls. Authoritative and accessible, Human Pluripotent Stem Cells: Methods and Protocols serves as an ideal guide to scientists conducting their own pluripotent cell research programs and makes great strides towards furthering human knowledge and, ultimately, improving the human condition. |
| cell therapy market size: Global Health Watch 5 People's Health Movement, Medact, Third World Network, Health Poverty Action, Medico International, Asociación Latinoamericana de Medicina Social, 2017-12-15 For over a decade, Global Health Watch has been the definitive source for alternative analysis on health. This new edition addresses the key challenges facing governments and health practitioners today, within the context of rapid shifts in global governance mechanisms and the UN’s Sustainable Development Goals. Like its predecessors, it challenges conventional wisdom while pioneering innovative new approaches to the field. Collaboratively written by academics and activists drawn from a variety of movements, research institutions and civil society groups, it covers some of the most pressing issues in world health, from the resurgence of epidemic diseases such as Ebola to the crisis in the WHO, climate change and the ‘war on drugs’. Combining rigorous analysis with practical policy suggestions, Global Health Watch 5 offers an accessible and compelling case for a radical new approach to health and healthcare across the world. |
| cell therapy market size: Stem Cells in Regenerative Medicine Alain A. Vertes, Nasib Qureshi, Arnold I. Caplan, Lee E. Babiss, 2015-12-02 This book is a unique guide to emerging stem cell technologies and the opportunities for their commercialisation. It provides in-depth analyses of the science, business, legal, and financing fundamentals of stem cell technologies, offering a holistic assessment of this emerging and dynamic segment of the field of regenerative medicine. • Reviews the very latest advances in the technology and business of stem cells used for therapy, research, and diagnostics • Identifies key challenges to the commercialisation of stem cell technology and avenues to overcome problems in the pipeline • Written by an expert team with extensive experience in the business, basic and applied science of stem cell research This comprehensive volume is essential reading for researchers in cell biology, biotechnology, regenerative medicine, and tissue engineering, including scientists and professionals, looking to enter commercial biotechnology fields. |
| cell therapy market size: Regenerative and Cell Therapy A. Keating, K. Dicke, N. Gorin, R. Weber, H. Graf, 2004-10-08 This book gives an updated review of the state of the art in regenerative cell therapy in the fields of cardiology, hematology, pediatrics, neurology, orthopedics and infectious diseases. The book emphasizes clinical advances as proof of concept in cell therapy based on the revolutionizing observation that regeneration can occur throughout the body even in highly differentiated organs like the heart and the neuronal system. It provides examples of breakthroughs in the clinical implementation of adult stem cell therapy. |
| cell therapy market size: Minimal Residual Disease Testing Todd E. Druley, 2018-11-15 This volume provides a concise yet comprehensive overview of minimal residual disease (MRD) testing. The text reviews the history of MRD testing, MRD testing for acute lymphoblastic leukemia/lymphoma, molecular diagnostics for MRD analysis in hematopoietic malignancies, the use of difference from normal flow cytometry in monitoring AML response, ML-DS for measurable residual disease detection, and advancements in next generation sequencing for detecting MRD. Written by experts in the field, Minimal Residual Disease Testing: Current Innovations and Future Directions is a valuable resource for hematologists, oncologists, pathologists, and radiologists on the variety of technologies available to detect MRD and how best to integrate these platforms into clinical practice. |
| cell therapy market size: Improving Healthcare Quality in Europe Characteristics, Effectiveness and Implementation of Different Strategies OECD, World Health Organization, 2019-10-17 This volume, developed by the Observatory together with OECD, provides an overall conceptual framework for understanding and applying strategies aimed at improving quality of care. Crucially, it summarizes available evidence on different quality strategies and provides recommendations for their implementation. This book is intended to help policy-makers to understand concepts of quality and to support them to evaluate single strategies and combinations of strategies. |
| cell therapy market size: Cell Therapy Adrian P. Gee, 2021-11-10 This new edition presents a fully-updated and expanded look at current Good Manufacturing Practice (cGMP) for cell therapy products. It provides a complete discussion of facility design and operation including details specific to cord blood banking, cell processing, vector production and qualification of a new facility. Several chapters cover facility infrastructure including cleaning and maintenance, vendor qualification, writing a Standard Operating Procedure, staff training, and process validation. The detailed and invaluable product information covers topics like labelling, release and administration, transportation and shipment, et al. Further chapters cover relevant topics like writing and maintaining investigational new drug applications, support opportunities in North America and the European Union, commercial cell processing and quality testing services, and financial considerations for academic GMP facilities. A chapter on future directions rounds out Cell Therapy: cGMP Facilities and Manufacturing making it essential reading for any cell therapy professional involved in the development, use, or management of this type of facility. |
| cell therapy market size: Biopharma in China Sven Agten, |
| cell therapy market size: Bioreactors Carl-Fredrik Mandenius, 2016-02-16 In this expert handbook both the topics and contributors are selected so as to provide an authoritative view of possible applications for this new technology. The result is an up-to-date survey of current challenges and opportunities in the design and operation of bioreactors for high-value products in the biomedical and chemical industries. Combining theory and practice, the authors explain such leading-edge technologies as single-use bioreactors, bioreactor simulators, and soft sensor monitoring, and discuss novel applications, such as stem cell production, process development, and multi-product reactors, using case studies from academia as well as from industry. A final section addresses the latest trends, including culture media design and systems biotechnology, which are expected to have an increasing impact on bioreactor design. With its focus on cutting-edge technologies and discussions of future developments, this handbook will remain an invaluable reference for many years to come. |
| cell therapy market size: Therapy with Cultured Cells Howard Green, 2019-05-08 In this book the author describes the discoveries in his laboratory that led to therapy with cultured cells. The first cultured cell type used for therapy was the keratinocyte of the epidermis, for the treatment of burns. Subsequent developments led to the use of cultured cells for the treatment of diseases of the eye, of the joints and of other diseases. Cultured cells for therapy are now being prepared by industries in the US, Japan and Korea and are used in the aforesaid countries, as well as in France, Sweden and Greece, for the treatment of disease. |
| cell therapy market size: Cellular Engineering and Cellular Therapies C.Th. Smit Sibinga, L.F.M.H. de Leij, 2013-03-09 Welcome to the City of Groningen, the center of the North of the Netherlands. Groningen is proud of the long lasting tradition of scientific symposia organised by the Sanquin Blood Bank. These Sanquin International Symposia on Blood Transfusion have become a true traditional event in Groningen, marking the early academic year and have contributed to the specific reputation of Groningen and its University in the scientific field of Transfusion Medicine. The growing tradition has also contributed to initiatives of both University, Province and the City of Groningen to bring science and industry together - BioMedCity Groningen. Such repu- tion does not just happen, but is the result of creative and scientific leadership, of vision and an open mind, to explore in a team spirit horizons. Groningen is particularly proud of this reputation thanks to its leadership, the Sanquin Blood Bank North-East. This year in particular the theme chosen some two years ago is extremely timely as it illustrates the activities and scientific interest of an integrated team which includes our regional Sanquin Blood Bank North-East and fits in the City initiatives within the concept of BioMedCity, Groningen. |
| cell therapy market size: The Changing Economics of Medical Technology Institute of Medicine, Committee on Technological Innovation in Medicine, 1991-02-01 Americans praise medical technology for saving lives and improving health. Yet, new technology is often cited as a key factor in skyrocketing medical costs. This volume, second in the Medical Innovation at the Crossroads series, examines how economic incentives for innovation are changing and what that means for the future of health care. Up-to-date with a wide variety of examples and case studies, this book explores how payment, patent, and regulatory policiesâ€as well as the involvement of numerous government agenciesâ€affect the introduction and use of new pharmaceuticals, medical devices, and surgical procedures. The volume also includes detailed comparisons of policies and patterns of technological innovation in Western Europe and Japan. This fact-filled and practical book will be of interest to economists, policymakers, health administrators, health care practitioners, and the concerned public. |
| cell therapy market size: Lung Stem Cells in Development, Health and Disease Nikolic, Marko Z., Hogan, Brigid L.M., 2021-04-01 Most organs in the adult human body are able to maintain themselves and undergo repair after injury; these processes are largely dependent on stem cells. In this Monograph, the Guest Editors bring together leading authors in the field to provide information about the different classes of stem cells present both in the developing and adult lung: where they are found, how they function in homeostasis and pathologic conditions, the mechanisms that regulate their behaviour, and how they may be harnessed for therapeutic purposes. The book focuses on stem cells in the mouse and human lung but also includes the ferret as an increasingly important new model organism. Chapters also discuss how lung tissue, including endogenous stem cells, can be generated in vitro from pluripotent stem cell lines. This state-of-the-art collection comprehensively covers one of the most exciting areas of respiratory science |
| cell therapy market size: Stem Cell Bioengineering Biju Parekkadan, Martin L. Yarmush, 2009 In stem cell research there are several key methods that, once mastered, can be extremely powerful. These methods enable you to rigorously test hypotheses, compare results to gold standards, and may even spur improvements to existing protocols. This book describes numerous methods to derive, manipulate, target, and prepare stem cells for clinical use. The methods described here help you derive and test human embryonic stem cells, analyze bone marrow stem cell function in vitro and in vivo, image a stem cell transplant, cryopreserve stem cells and differentiate stem cells using microscale tec. |
| cell therapy market size: From Research to Reality The Expert Panel on the Approval and Use of Somatic Gene Therapies in Canada, 2020-11-05 From Research to Reality describes the stages involved in the approval and use of gene therapies in Canada, and examines challenges associated with regulatory oversight, manufacturing, access, and affordability, and identifies promising approaches to address them. |
| cell therapy market size: The Stem Cell Cure Gaurav K. Goswami, Kerry Johnson, 2020-03-31 The 150+ year lifespan of our ancient ancestors can be achieved once again by harnessing the power of our own cells with The Stem Cell Cure! Renowned regenerative and restorative sports medicine doctor Gaurav Goswami, M.D. provides advanced minimally invasive, non-surgical treatments to help his patients get back to peak performance levels – no matter their age. Harnessing the transformative power of stem cells is central to his expertise. In fact, stem cell therapy is proven to be effective in the treatment of many common conditions from arthritis and back pain to Alzheimer’s, Parkinson’s, and cancer. This book is an accessible and informative introduction to the amazing powers of Stem Cell Therapy – the biggest revolution in medicine since the discovery of penicillin, and a wave of the future. Co-authored by bestselling author and popular keynote speaker Kerry Johnson MBA PhD, The Stem Cell Cure provides specific ways for readers to boost their health and vitality for a lifetime by recovering, regenerating, and repairing injuries and disease. |
| cell therapy market size: Immunopharmacogenomics Yusuke Nakamura, 2015-09-18 This book proposes immunogenomics, or immunopharmacogenomics, as the next-generation big science to uncover the role that the immune system plays in the pathogenesis of many diseases, by summarizing the importance of the deep sequencing of T-cell and B-cell receptors. Immunogenomics/immunopharmacogenomics, a genetic characterization of the immune system made possible by next-generation sequencing (NGS), will be important for the further understanding of the pathogenesis of various disease conditions. Abnormal immune responses in the body lead to development of autoimmune diseases and food allergies. Rejection of recipient cells and tissues, as well as severe immune reactions to donor cells, is also the result of uncontrolled immune responses in the recipient body. There have been many reports indicating that activated immune responses caused by the interaction of drugs and HLA are present in drug-induced skin hypersensitivity and liver toxicity. The importance of the host immune responses has been recognized in cancer treatments, not only for immunotherapy but also for cytotoxic agents and molecular targeted drugs. Hence, characterization of the T-cell receptor and B-cell receptor repertoire by means of NGS deep sequencing will ultimately make possible the identification of the molecular mechanisms that underlie various diseases and drug responses. In addition, this approach may contribute to the identification of antigens associated with the onset or progression of autoimmune diseases as well as food allergies. Although the germline alterations and somatic mutations have been extensively analyzed, changes or alterations of the immune responses during the course of various disease conditions or during various treatments have not been analyzed. It is also clear that computational analyses to draw meaningful inferences of functional recognition receptors on the immune cells remain a huge challenge. |
2023 CGT industry survey - Deloitte United States
Deloitte conducted a survey to assess the current state of the cell and gene therapy (CGT) industry and identify trends that are poised to shape the industry in the years ahead.
CELL & GENE THERAPY - Coherent Market Insights
CELL & GENE THERAPY MARKET MAJOR DRIVERS Increasing prevalence of cardiovascular disease and cancer. Increasing product approval and launch . Coherent Market Insights is a …
Cell, Gene, & RNA Therapy Landscape - asgct.org
Jan 12, 2024 · Across the pipeline in 2023, RNA therapies had the largest number of approvals at eight, including five approvals for COVID-19 vaccines.
The next S curve of cell therapy: Opportunities across the …
Includes only immune-cell effector therapies with predicted worldwide 2027 revenues, including both autologous and allogeneic therapies; analysis utilized analyst-forecasted revenues and …
2023 WuXi AppTec Investor Day WuXi ATU: A Global CTDMO …
• Global cell and gene therapy CDMO services market increases from USD0.8 billion in 2015 to USD3.9 billion in 2022 with a CAGR of 24.6%. The market will continue to grow to USD11.6 …
Global CAR-T Cell Therapy Market Market Size, Forecasts, …
Global CAR-T Cell Therapy Market – Market Size, Forecasts, Trials & Trends, 2023 | BioInformant TABLE OF CONTENTS 1. REPORT OVERVIEW 19 1.1 Statement of the Report …
Cell Therapy Industry Research Report 2023
Cell Therapy. The Cell Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for …
CAR-T Cell Therapy Market Analysis - targo-consulting.com
The global CAR-T Cell therapy market was estimated at US$ 167.9 million in 2018 and is expected to witness a CAGR of 46.1% until 20281. The market is still very small since only 2 …
Pricing, Reimbursement and Market Access Trends for Cell
• Cell / gene therapies with highest annual visible ex-factory price are: • US was Rethymic (Allogeneic processed thymus tissue–agdc) at $2.7M • Europe was Libmeldy (atidarsagene …
Biopharma portfolio strategy in the era of cell and gene therapy
Many biopharma companies are investing in cell and gene therapy, albeit cautiously, amid a nascent market. Understanding investment opportunities and entry strategies will help guide …
Analytics - Eurofins Scientific
antigen receptor T cell (CAR-T) products since 2017 have promoted exponential expansion of the cell therapy landscape over the past several years. The global market size is estimated to …
Landscape of cancer cell therapies: trends and real-world data …
In this update, we provide an in-depth analysis of the current cell therapy landscape, including the development pipeline and clinical trials. We have also analysed real- world data to describe...
China’s Stem Cell Industry: Fast Growing driven by Demand, …
• The global stem cell therapy market in 2019 was around US$148 billion. It is estimated that the market will grow to near US$242 billion in 2024, representing a compound annual growth rate …
Cell Therapy Market Outlook Report: Industry Size, Market …
The Global Cell Therapy Market valued at USD 15.4 billion in 2024, is expected to grow by 19.054% CAGR to reach market size worth USD 90.1 billion by 2034. Cell therapy, a …
Evaluating Immune Cell Therapy Potency - chem-agilent.com
The global cell therapy market size was valued at $7.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 14.5% from 2021 to 2028.
Global CAR-T Cell Therapy Market Market Size, Forecasts, …
Global CAR-T Cell Therapy Market – Market Size, Forecasts, Trials & Trend (2021) | BioInformant TABLE OF CONTENTS 1. REPORT OVERVIEW 1.1 Statement of the Report 1.2 Executive …
White Paper Private Market Opportunity for CAR T-cell …
Chimeric antigen receptor (CAR) T-cell therapy is a next generation therapy which currently treats patients with certain haematological cancers including acute lymphoblastic leukaemia (ALL), …
Essential guide to cell and gene therapy commercialization
Cell and gene therapy: a dynamic and innovative space they continue to be keen on these one-time therapies with curative intent1, and the annual market growth rate is expected to be about …
Cell Therapy Market Size, Share & Trends Analysis Report By …
The global cell therapy market size is expected to reach USD 8.8 billion by 2027 at a CAGR of 5.4% over the forecast period, according to a new report by Grand View Research, Inc. …
Driving the next wave of innovation in CAR T-cell therapies
CAR T-cell therapies have transformative potential as a new type of cancer treatment that uses the immune system to fight diseases. CAR T involves genetically engineering T cells (either a …
2023 CGT industry survey - Deloitte United States
Deloitte conducted a survey to assess the current state of the cell and gene therapy (CGT) industry and identify trends that are poised to shape the industry in the years ahead.
CELL & GENE THERAPY - Coherent Market Insights
CELL & GENE THERAPY MARKET MAJOR DRIVERS Increasing prevalence of cardiovascular disease and cancer. Increasing product approval and launch . Coherent Market Insights is a global market …
Cell, Gene, & RNA Therapy Landscape - asgct.org
Jan 12, 2024 · Across the pipeline in 2023, RNA therapies had the largest number of approvals at eight, including five approvals for COVID-19 vaccines.
The next S curve of cell therapy: Opportunities across the …
Includes only immune-cell effector therapies with predicted worldwide 2027 revenues, including both autologous and allogeneic therapies; analysis utilized analyst-forecasted revenues and …
2023 WuXi AppTec Investor Day WuXi ATU: A Global CTDMO …
• Global cell and gene therapy CDMO services market increases from USD0.8 billion in 2015 to USD3.9 billion in 2022 with a CAGR of 24.6%. The market will continue to grow to USD11.6 billion …
Global CAR-T Cell Therapy Market Market Size, Forecasts, …
Global CAR-T Cell Therapy Market – Market Size, Forecasts, Trials & Trends, 2023 | BioInformant TABLE OF CONTENTS 1. REPORT OVERVIEW 19 1.1 Statement of the Report 19 1.2 Executive …
Cell Therapy Industry Research Report 2023
Cell Therapy. The Cell Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the …
CAR-T Cell Therapy Market Analysis - targo-consulting.com
The global CAR-T Cell therapy market was estimated at US$ 167.9 million in 2018 and is expected to witness a CAGR of 46.1% until 20281. The market is still very small since only 2 treatments for …
Pricing, Reimbursement and Market Access Trends for Cell
• Cell / gene therapies with highest annual visible ex-factory price are: • US was Rethymic (Allogeneic processed thymus tissue–agdc) at $2.7M • Europe was Libmeldy (atidarsagene …
Biopharma portfolio strategy in the era of cell and gene therapy
Many biopharma companies are investing in cell and gene therapy, albeit cautiously, amid a nascent market. Understanding investment opportunities and entry strategies will help guide their …
Analytics - Eurofins Scientific
antigen receptor T cell (CAR-T) products since 2017 have promoted exponential expansion of the cell therapy landscape over the past several years. The global market size is estimated to …
Landscape of cancer cell therapies: trends and real-world data
In this update, we provide an in-depth analysis of the current cell therapy landscape, including the development pipeline and clinical trials. We have also analysed real- world data to describe...
China’s Stem Cell Industry: Fast Growing driven by Demand, …
• The global stem cell therapy market in 2019 was around US$148 billion. It is estimated that the market will grow to near US$242 billion in 2024, representing a compound annual growth rate …
Cell Therapy Market Outlook Report: Industry Size, Market …
The Global Cell Therapy Market valued at USD 15.4 billion in 2024, is expected to grow by 19.054% CAGR to reach market size worth USD 90.1 billion by 2034. Cell therapy, a revolutionary …
Evaluating Immune Cell Therapy Potency - chem-agilent.com
The global cell therapy market size was valued at $7.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 14.5% from 2021 to 2028.
Global CAR-T Cell Therapy Market Market Size, Forecasts, …
Global CAR-T Cell Therapy Market – Market Size, Forecasts, Trials & Trend (2021) | BioInformant TABLE OF CONTENTS 1. REPORT OVERVIEW 1.1 Statement of the Report 1.2 Executive Summary …
White Paper Private Market Opportunity for CAR T-cell …
Chimeric antigen receptor (CAR) T-cell therapy is a next generation therapy which currently treats patients with certain haematological cancers including acute lymphoblastic leukaemia (ALL), …
Essential guide to cell and gene therapy commercialization
Cell and gene therapy: a dynamic and innovative space they continue to be keen on these one-time therapies with curative intent1, and the annual market growth rate is expected to be about 22% …
Cell Therapy Market Size, Share & Trends Analysis Report By …
The global cell therapy market size is expected to reach USD 8.8 billion by 2027 at a CAGR of 5.4% over the forecast period, according to a new report by Grand View Research, Inc. Cellular …
Driving the next wave of innovation in CAR T-cell therapies
CAR T-cell therapies have transformative potential as a new type of cancer treatment that uses the immune system to fight diseases. CAR T involves genetically engineering T cells (either a …
